Laufende Studien

INAVO123
fortgeschritten/metastasiert
HR+/HER2- PIK3CA+
Mammakarzinom
Phase III

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (INAVO123)

ASCENT-05
post-neoadjuvant
Triple negatives Mammakarzinom
Phase III

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

CAMBRIA-2
adjuvant
HR+/HER2- Mammakarzinom
Phase III

A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

GeparPiPPa
neoadjuvant
HER2+/HR+/PIK3CA mutiertes Mammakarzinom
Phase II

A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer

ERIKA/ABCSG 63
neoadjuvant
HR+ / HER2- Mammakarzinom
Phase II

Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer: An open-label, two-arm, randomized, phase II study of elacestrant plus ribociclib vs. AI (plus GnRH agonist in pre-/perimenopausal women and men) plus ribociclib as neoadjuvant therapy for endocrine-responsive HER2-negative early breast cancer

BE6A LUNG-02
Stadium IIIB, IIIC, IV NSCLC
PD-L1 TC ≥50%
1^st line Therapie
Phase III

An open-label, randomized, controlled phase 3 study of sigvotatug vedotin in combination with pembrolizumab compared with pembrolizumab monotherapy as first-line treatment in participants with PD-L1 high (≥50% of tumor cells expressing PD-L1), locally advanced, unresectable, or metastatic non-small cell lung cancer

BRUIN-CLL-211
r/r CLL/SLL
1-3 Vortherapien inklusive cBTKi
Phase II

A Phase 2, Open-label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants with Relapsed or Refactory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

BGB-16673-302
r/r CLL/SLL
>1 Vortherapie inklusive
cBTKi und BCL2i
Phase III

A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors

BELLWAVE-011
CLL/SLL
1^st line Therapie
Phase III

A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

CLL 16
Hochrisiko CLL
1^st line Therapie
Phase III

A Prospective, Open-label, Multicentre, Randomized, Phase-3-trial of Acalabrutinib, Obinutuzumab and Venetoclax (GAVE) Compared to Obinutuzumab and Venetoclax (GVE) in Previously Untreated Patients With High Risk (17P-deletion, TP53-mutation or Complex Karyotype) Chronic Lymphatic Leukemia (CLL)

ELEMENT-MDS
Myelodysplastisches Syndrom
Neu diagnostiziert, ESA naiv
Phase III

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoietin-stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD)

Deutschsprachige Informationen für Patienten und Angehörige finden Sie hier 

SYBIL
palliativ
Solide Tumoren
Beobachtungs-/Diagnostikstudie

SIBYL: obServation of therapy response with lIquid BiopsY evaLuation